Crispr Therapeutics AG is a biotechnology business with stocks listed in the US. CRISPR Therapeutics shares (CRSP) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$71.14 – an increase of 6.61% over the previous week. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
Low costs
Our top pick for
Dividend investing
CRISPR Therapeutics's shares were split on a 333333:100 basis on 19 July 2016. So if you had owned 100 shares the day before the split, the next day you would own 333333 shares. This wouldn't directly have changed the overall worth of your CRISPR Therapeutics shares – just the quantity. However, indirectly, the new 100% lower share price could have impacted the market appetite for CRISPR Therapeutics shares which in turn could have impacted CRISPR Therapeutics's share price.
| 52-week range | US$37.55 - US$76.19 |
|---|---|
| 50-day moving average | US$50.3758 |
| 200-day moving average | US$52.3052 |
| Target price | US$87.78 |
| PE ratio | N/A |
| Dividend yield | US$0 (0%) |
| Earnings per share (TTM) | US$-4.47 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $71.14
| 1 week (2023-11-30) | 6.61% |
|---|---|
| 1 month (2023-11-07) | 21.44% |
| 3 months (2023-09-07) | 44.18% |
| 6 months (2023-06-07) | 13.32% |
| 1 year (2022-12-07) | 40.57% |
|---|---|
| 2 years (2021-12-07) | -9.25% |
| 3 years (2020-12-07) | -52.48% |
| 5 years (2018-12-07) | 102.91% |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Over the last 12 months, CRISPR Therapeutics's shares have ranged in value from as little as US$37.55 up to US$76.19. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CRISPR Therapeutics's is 1.811. This would suggest that CRISPR Therapeutics's shares are more volatile than the average for this exchange and represent, relatively speaking, a higher risk (but potentially also market-beating returns).
| Revenue TTM | US$170 million |
|---|---|
| Gross profit TTM | US$-570,697,000 |
| Return on assets TTM | -11.93% |
| Return on equity TTM | -19.21% |
| Profit margin | -207.95% |
| Book value | 21.753 |
| Market capitalisation | US$5.7 billion |
TTM: trailing 12 months
We're not expecting CRISPR Therapeutics to pay a dividend over the next 12 months.
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and VCTX211, an investigational, allogeneic, gene-edited, stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
What you need to know about investing in Shein from Australia.
Looking for the best performing stocks in Australia? We update this list weekly.
If you're thinking of trading stocks with Tiger Brokers, check out our review of this online broker's fees, safety and pros and cons first.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Steps to owning and managing Caltex Australia shares from .
Looking for alternative investments? With a ROI of up to 3,593% lego may be worth considering. Read on to find out which lego sets are worth the investment.
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
Learn about the money market and everyday consumer money market products.
Equity crowdfunding offers a unique opportunity for investors and for Australian startups, but Australia’s regulatory framework surrounding crowdfunding still lags behind the rest of the world.
Follow these tips to find the best share trading platform for you.
